Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Mandelic Acids; Oxybutynin; Trospium chloride

Criteria

Inclusion Criteria:

• Patient presents symptoms of overactive bladder

• Patient has age associated memory impairment

• No acute or unstable medical conditions

Exclusion Criteria:

• History of alcohol or substance abuse within 1 year prior to study

• Has donated in excess of 500mL of blood or plasma in the 30 days prior to study

• Has known bleeding disorder (hemophilia)

• Previous abdominal bypass surgery for obesity